About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

AnGes, Inc.(4563) Summary

4563
TSE Growth
AnGes, Inc.
61
JPY
-3
(-4.69%)
Apr 4, 3:30 pm JST
0.41
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
58.5
Apr 4, 11:29 pm JST
Summary Chart Historical News Financial Result
PER
PBR
9.73
Yield
ー%
Margin Trading Ratio
8.26
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
64 JPY 0.43 USD
Previous Close Apr 3
64 JPY 0.43 USD
High Apr 4, 9:14 am
65 JPY 0.44 USD
Low Apr 4, 12:44 pm
60 JPY 0.41 USD
Volume
8,041,800
Trading Value
0.50B JPY 3.41M USD
VWAP
62.01 JPY 0.43 USD
Minimum Trading Value
6,100 JPY 41 USD
Market Cap
0.02T JPY 0.14B USD
Number of Trades
500
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Slightly High
1-Year Average
575
1-Year High Sep 20, 2024
9,245
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 1,449,400 35,710,200 24.64
Mar 21, 2025 1,446,600 28,650,900 19.81
Mar 14, 2025 1,451,600 26,578,600 18.31
Mar 7, 2025 1,450,800 26,744,900 18.43
Feb 28, 2025 1,448,800 32,034,300 22.11
Company Profile
AnGes, Inc. is a biotech venture founded by an Osaka University professor, developing gene therapies and other pharmaceuticals. The company also sells treatments for intractable diseases.
Sector
Pharmaceuticals
AnGes, Inc. is a biotech venture originating from Osaka University Medical School, focusing on the development and sale of pharmaceuticals, particularly gene therapies. The company also provides contract testing services, primarily for rare genetic disease screening. Its subsidiary, EmendoBio Inc., possesses advanced genome editing technologies and is engaged in research and development of new treatments using genome editing products. In 2019, AnGes obtained conditional and time-limited manufacturing and marketing approval for "Collategene," the world's first plasmid DNA-based gene therapy product. The company has entered into an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for the Japanese market, and has begun sales, recording product sales revenue.